Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Sophie Vasseur

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2339-8854; OpenAlex author ID A5082874632. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 19

  1. Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer. Co-author DOI 10.1172/jci197733↗
  2. Co-translational O-glycosylation driven by GALNTs spatial reprogramming fosters pancreatic cancer growth Co-author DOI 10.64898/2026.09.04.749345↗
  3. The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. Last author DOI 10.1126/sciadv.adu2276↗
  4. CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness. Co-author DOI 10.1126/scisignal.abg8191↗
  5. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. Last author DOI 10.15252/embj.2021110466↗
  6. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s42003-021-02508-0↗
  7. Fountain of youth of pancreatic cancer cells: the extracellular matrix. First author DOI 10.1038/s41420-017-0004-7↗
  8. LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. Co-author DOI 10.1158/0008-5472.can-15-2790↗
  9. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  10. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Last author DOI 10.1038/ncomms16031↗
  11. Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze. First author DOI 10.1002/ijc.29501↗
  12. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/cdd.2016.18↗
  13. Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Co-author DOI 10.1172/jci87734↗
  14. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Co-author DOI 10.18632/oncotarget.10776↗
  15. Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling. Co-author DOI 10.1038/cddis.2014.557↗
  16. [Pancreatic adenocarcinoma: a tumor highly dependent on lipoproteins]. Co-author DOI 10.1051/medsci/20153108009↗
  17. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Last author DOI 10.1073/pnas.1421601112↗
  18. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Last author DOI 10.1073/pnas.1219555110↗
  19. The metabolic facet of pancreatic cancer: how hypoxia shapes fatal cancer cells. First author DOI 10.4161/cc.24489↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard Tomasini · 13 shared papers, 2013–2026 · strength 1.36
  2. Fabienne Guillaumond · 14 shared papers, 2013–2026 · strength 1.30
  3. François Bertucci · 5 shared papers, 2021–2026 · strength 0.80
  4. Juan Iovanna · 12 shared papers, 2013–2022 · strength 0.76
  5. Nelson Dusetti · 7 shared papers, 2013–2026 · strength 0.55
  6. Jérémy Nigri · 7 shared papers, 2015–2022 · strength 0.49
  7. Julie Leca · 7 shared papers, 2013–2022 · strength 0.48
  8. Zainab Hussain · 2 shared papers, 2025–2026 · strength 0.44
  9. Victoire Gouirand · 4 shared papers, 2015–2022 · strength 0.38
  10. Véronique Secq · 6 shared papers, 2015–2018 · strength 0.28
  11. Mehdi Ouaïssi · 6 shared papers, 2015–2018 · strength 0.27
  12. Orianne Olivares · 4 shared papers, 2013–2017 · strength 0.25
  13. Julie Roques · 5 shared papers, 2015–2018 · strength 0.24
  14. Moacyr Jesus Barreto de Melo Rêgo · 1 shared paper, 2026 · strength 0.24
  15. Rebecca Bennion · 1 shared paper, 2026 · strength 0.24
  16. Frédéric Bard · 1 shared paper, 2026 · strength 0.24
  17. Eric Mas · 1 shared paper, 2026 · strength 0.24
  18. Brice Chanez · 1 shared paper, 2026 · strength 0.24
  19. Martin James Humphries · 1 shared paper, 2026 · strength 0.24
  20. Georgios Efthymiou · 1 shared paper, 2025 · strength 0.20
  21. Christian Bressy · 4 shared papers, 2015–2018 · strength 0.20
  22. Céline Loncle · 5 shared papers, 2013–2017 · strength 0.20
  23. Sébastien Martinez · 2 shared papers, 2016–2022 · strength 0.18
  24. Tristan Gicquel · 2 shared papers, 2017–2022 · strength 0.17
  25. Jared R. Mayers · 2 shared papers, 2017–2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.